← Latest
Brief

Moderna's Melanoma Vaccine Cuts Relapse Risk 42%

Moderna and Merck's personalized mRNA vaccine cut melanoma recurrence or death by 42%, yet Moderna fell 17.6% as the effect trailed earlier trial results.

Share ↗
Syringe in front of the Moderna logo
Image: Ars Technica

Next edition

Nvidia Opens Flora, Its Robot Video Labeler

AI Secret

AI Secret Membership

Choose your edge.

Independent AI analysis. Your own agent to take it further.

AI Secret

AI Secret Membership · Step 1 of 2

Your next chapter starts here.

Enter your email to choose your membership. Use the same email if you already read AI Secret.

Already a member? Sign in

AI Secret

Your free daily briefing

Check your inbox.

We've sent a confirmation link to . Follow the link to verify your email and complete your free subscription.

Free membership includes the daily briefing. Paid Deep Dives require a paid membership.